arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cardio Diagnostics Holdings, Inc.

CDIO

$1.66 ▲ +0.01 (+0.61%) at close

6 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Cardio Diagnostics Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.9M

Dividend Yield —

Revenue Growth -57.5% ↘

Op. Margin —

ROIC -73.5% ↘

FCF / Share $-3.38 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$14.82K

↓ -57.5% —

Net Income Profit after all expenses

$-6.50M

↑ +22.5% —

FCF / Share Free cash flow per share

$-3.38

↑ +41.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	-57.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-819%)	104.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1206%)	1696.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+21104%)	5.4% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-32%)	—	—
EPS Growth YoY (%)	60.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1316.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	56.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-184.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	22.5% Good ↑ Good Improving Year-over-year change in net income	-0.1% Weak ↑ Weak Improving Year-over-year change in net income	-79.7% Weak Weak Year-over-year change in net income	-651.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	41.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1079.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	70.1% Excellent Excellent Year-over-year change in free cash flow	-227.7% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	149.9% Excellent Excellent Compound annual revenue growth over 3 years	238.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-73.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-69.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-193.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-83.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-58.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-83.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-78.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-162.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-72.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-56.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-93.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-721%)	-87.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-685%)	-283.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1988%)	-108.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-822%)	-58.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-487%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	-438.08x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-448.81x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1.08x Weak Weak Operating income divided by interest expense Optimal: > 5x	-780.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.01	$0.04	$0.00	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-3.71	$-9.35	$-0.66	$-1.51	$-0.53	—
Free Cash Flow per Share (USD)	$-3.38	$-5.81	$-0.49	$-1.65	$-0.50	—
Book Value per Share (USD)	$3.82	$6.24	$0.14	$0.45	$0.87	—
Tangible Book Value per Share (USD)	$3.82	$6.24	$0.14	$0.45	$0.87	—
Basic Weighted Avg Shares (shares)	1.75M	896,424	12.69M	3.09M	1.16M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$5.32M	$8.16M	$1.92M	$3.94M	—	—
Total Equity (USD)	$6.97M	$9.56M	$2.96M	$4.30M	$1.07M	$60.37K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$14.82K	$34.89K	$17.07K	$950.00	$901.00	—
Depreciation Expense (USD)	$160.06K	$113.78K	$3.79K	$0.00	—	—
Net Income, GAAP (USD)	$-6.50M	$-8.38M	$-8.38M	$-4.66M	$-620.45K	—
Operating Cash Flow (USD)	$-5.73M	$-4.99M	$-5.67M	$-5.09M	$-585.29K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 22 quarters

Cardio Diagnostics Holdings, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CDIO with peers